Comparison of Oxidative Stress Parameters in Heart Failure Patients Depending on Ischaemic or Nonischaemic Aetiology
Table 1
Clinical and laboratory characteristics of patients included into the study with comparison of study groups. Categorical variables are shown as percentages and numerical variables as medians with lower and upper quartiles where appropriate.
Ischaemic ()
Nonischaemic ()
value
General characteristics
Male () (%)
416 (86,8)
249 (84,4)
NS
Age (years)
56,00 (52,00–61,00)
50,00 (39,00–56,00)
0,001
BMI (kg/m2)
26,45 (23,88-29,29)
25,77 (22,32-29,07)
0,01
Duration of symptoms before inclusion (months)
33,87 (13,6-66,27)
33,83 (2,17-73,1)
NS
NYHA class
3 (2-3)
3 (2-3)
NS
Measured VO2 (ml/min)
1,10 (0,82-1,38)
1,16 (0,92-1,43)
0,05
Maximum measured VO2 (ml/min/kg b.m.)
14,6 (11,9-17,9)
15,6 (12,6-19,5)
0,01
Measured VCO2 (l/min)
1,07 (0,77-1,38)
1,13 (0,86-1,39)
0,01
LVEDD (mm)
69,00 (63,00-75,00)
71,00 (64,00-78,00)
0,05
LVEDV (ml)
209,0 (167,0-271,0)
245,0 (181,0-314,0)
0,001
LVEF (%)
24,00 (20,00-30,00)
23,00 (20,00-29,00)
NS
Basic biochemistry
Haemoglobin (mmol/l)
14,02 (13,05-14,83)
14,18 (13,05-15,31)
0,05
Creatinine (μmol/l)
88,00 (73,00–108,0)
83,00 (71,0–99,0)
0,01
Serum protein concentration (g/l)
71,00 (67,00–75,00)
71,0 (67,00–76,00)
NS
Albumin (g/l)
42,00 (39, 00–44,00)
42,00 (39,00–45,00)
NS
Fasting glucose (mmol/l)
5,60 (5,00-6,40)
5,50 (4,90-6,10)
0,05
Total cholesterol (mmol/l)
4,26 (3,65-5,23)
4,32 (3,62-5,19)
NS
Triglycerides (mmol/l)
1,21 (0,88-1,74)
1,21 (0,91-1,71)
NS
Cholesterol HDL (mmol/l)
1,16 (0,95-1,41)
1,14 (0,91-1,40)
NS
Cholesterol LDL (mmol/l)
2,43 (1,87 - 3,16)
2,48 (1,94-3,19)
NS
NT-proBNP (pg/ml)
1317 (628,4-2863)
1601 (658,6-3562)
NS
Comorbidities
Diabetes () (%)
162 (33,8)
57 (19,3)
0,001
Arterial hypertension () (%)
287 (59,9)
136 (46,1)
0,001
Atrial fibrillation () (%)
85 (17,7)
98 (33,2)
0,001
ICD presence () (%)
75 (15,7)
47 (15,9)
NS
Smoker () (%)
361 (75,4)
202 (68,5)
0,05
Pharmacotherapy
Beta-blockers () (%)
472 (98,5)
287 (97,3)
NS
ACE inhibitors () (%)
417 (87,2)
251 (85,1)
NS
Angiotensin-2 receptor blockers () (%)
48 (10,0)
34 (11,5)
NS
Loop diuretics () (%)
403 (84,1)
276 (93,6)
0,05
Thiazide diuretics () (%)
52 (10,9)
47 (15,9)
0,05
Aldosterone receptor antagonist () (%)
433 (90,4)
281 (95,3)
NS
Statins () (%)
364 (76,0)
142 (48,1)
0,001
Fibrates () (%)
17 (3,55)
11 (3,73)
NS
Digitalis () (%)
193 (40,3)
159 (53,9)
0,001
XOi () (%)
142 (29,6)
133 (45,1)
0,001
BMI: body mass index; NYHA: New York Heart Association functional class; VO2: maximum oxygen output; LVEDD: left ventricle end-diastolic diameter; LVEDV: left ventricle end-diastolic volume; LVEF: left ventricle ejection fraction; NT-proBNP: N-terminal pro-B-type natriuretic peptide; ICD: implantable cardioverter defibrillator; ACE-inhibitor: angiotensin-converting enzyme inhibitor; XOi: xanthine oxidase inhibitors; NS: nonsignificant.
